|
| 36329348 | Cost-effectiveness of minimally invasive partial nephrectomy and percutaneous cryoablation for cT1a renal cell carcinoma. | Eur Radiol | 2023 |
| 37524096 | Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial. | Lancet | 2023 |
| 37659025 | Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial. | Target Oncol | 2023 |
| 37321822 | [<sup>68</sup>Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis. | J Nucl Med | 2023 |
| 37255402 | FH Variant Pathogenicity Promotes Purine Salvage Pathway Dependence in Kidney Cancer. | Cancer Discov | 2023 |
| 37085424 | Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma. | Eur Urol | 2023 |
| 37183095 | Disparate Utilization of Breast Conservation Therapy in the Surgical Management of Early-Stage Breast Cancer. | Clin Breast Cancer | 2023 |
| 37182269 | Comparative analyses define differences between BHD-associated renal tumour and sporadic chromophobe renal cell carcinoma. | EBioMedicine | 2023 |
| 37229788 | Contemporary care patterns in the management of small renal masses. | Am J Manag Care | 2023 |
| 36403677 | Perioperative Nephrectomy Outcomes for Patients with Liver Disease: Implications for Liver Transplant Candidates. | Urology | 2023 |
| 36397716 | Transcriptomic recurrence score improves recurrence prediction for surgically treated patients with intermediate-risk clear cell kidney cancer. | Cancer Med | 2023 |
| 36774933 | Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. | Lancet | 2023 |
| 36773955 | Fumarate Hydratase Variants and Their Association With Paraganglioma/Pheochromocytoma. | Urology | 2023 |
| 34724198 | Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing. | Cancer | 2022 |
| 37145562 | Decisional Regret and Financial Toxicity among Patients with Benign Renal Masses. | Urol Pract | 2022 |
| 36500549 | CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells. | Molecules | 2022 |
| 35874919 | Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancers. | iScience | 2022 |
| 36310638 | Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL. | J Kidney Cancer VHL | 2022 |
| 36100483 | Epidemiology of Renal Cell Carcinoma: 2022 Update. | Eur Urol | 2022 |
| 36128328 | Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. | Oncotarget | 2022 |
| 34991070 | Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2022 |
| 32972793 | Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier. | Eur Urol | 2021 |
| 37145397 | Sequencing of Renal Mass Biopsy and Ablation: Results from the National Cancer Database. | Urol Pract | 2021 |
| 33512909 | Telemedicine-Based Perioperative Management of Pheochromocytoma in a Patient With Von Hippel Lindau Disease: A Case Report. | A A Pract | 2021 |
| 33592176 | A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. | Lancet | 2021 |
| 33579573 | Advances in the Characterization of Clear Cell Papillary Renal Cell Carcinoma: Identifying the Sheep in Wolf's Clothing. | Eur Urol | 2021 |
| 33914106 | <sup>68</sup>Ga-FAPI-46 and <sup>18</sup>F-FDG PET/CT in a patient with immune-related thyroiditis induced by immune checkpoint inhibitors. | Eur J Nucl Med Mol Imaging | 2021 |
| 34424955 | Adverse Histopathologic Characteristics in Small Papillary Renal Cell Carcinomas Have Minimal Impact on Prognosis. | Am J Clin Pathol | 2021 |
| 34297683 | HIF2 Inhibition for von-Hippel Lindau Associated Kidney Cancer: Will Urology Lead or Follow? | Urol Oncol | 2021 |
| 34270355 | Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective. | Radiographics | 2021 |
| 34343338 | Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. | Cancer | 2021 |
| 34034966 | Papillary renal cell carcinoma: Review. | Urol Oncol | 2021 |
| 33408053 | Novel Liquid Biomarkers and Innovative Imaging for Kidney Cancer Diagnosis: What Can Be Implemented in Our Practice Today? A Systematic Review of the Literature. | Eur Urol Oncol | 2021 |
| 32250730 | Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II Trial. | J Urol | 2020 |
| 34017908 | The Association Between the Affordable Care Act and Insurance Status, Stage and Treatment in Patients with Testicular Cancer. | Urol Pract | 2020 |
| 31782041 | Understanding racial disparities in renal cell carcinoma incidence: estimates of population attributable risk in two US populations. | Cancer Causes Control | 2020 |
| 32101890 | High WHO/ISUP Grade and Unfavorable Architecture, Rather Than Typing of Papillary Renal Cell Carcinoma, May Be Associated With Worse Prognosis. | Am J Surg Pathol | 2020 |
| 33081400 | Radiomic Features and Machine Learning for the Discrimination of Renal Tumor Histological Subtypes: A Pragmatic Study Using Clinical-Routine Computed Tomography. | Cancers (Basel) | 2020 |
| 32861253 | Analysis of guideline recommended use of renal mass biopsy and association with treatment. | Can J Urol | 2020 |
| 32600536 | Adjuvant Therapy for Localized High-Risk Renal Cell Carcinoma. | Urol Clin North Am | 2020 |
| 32955409 | Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. | JCO Oncol Pract | 2020 |
| 32471985 | Ovarian BDNF promotes survival, migration, and attachment of tumor precursors originated from p53 mutant fallopian tube epithelial cells. | Oncogenesis | 2020 |
| 32413184 | Estimation of the carrier frequency of fumarate hydratase alterations and implications for kidney cancer risk in hereditary leiomyomatosis and renal cancer. | Cancer | 2020 |
| 32494005 | Oncometabolites suppress DNA repair by disrupting local chromatin signalling. | Nature | 2020 |
| 32516030 | The Role of Opioids and Their Receptors in Urological Malignancy: A Review. | J Urol | 2020 |
| 32222350 | Transcriptomics in RCC. | Urol Oncol | 2020 |
| 30561791 | Risk factors for metachronous bilateral renal cell carcinoma: A surveillance, epidemiology, and end results analysis. | Cancer | 2019 |
| 30059717 | Determinants of Active Surveillance in Patients With Small Renal Masses. | Urology | 2019 |
| 31217358 | Development of a 2-dimensional atlas of the human kidney with imaging mass cytometry. | JCI Insight | 2019 |
| 31326218 | Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. | Eur Urol | 2019 |